Last reviewed · How we verify
AZD3759
AZD3759 is a small molecule inhibitor of the EGFR pathway.
AZD3759 is a small molecule inhibitor of the EGFR pathway. Used for Non-small cell lung cancer, Head and neck cancer.
At a glance
| Generic name | AZD3759 |
|---|---|
| Sponsor | Guangdong Association of Clinical Trials |
| Drug class | EGFR inhibitor |
| Target | EGFR |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
AZD3759 works by selectively inhibiting the activity of the epidermal growth factor receptor (EGFR), a protein that plays a key role in the development and progression of certain types of cancer. By blocking EGFR, AZD3759 can help slow or stop the growth of cancer cells.
Approved indications
- Non-small cell lung cancer
- Head and neck cancer
Common side effects
- Diarrhea
- Fatigue
- Nausea
- Vomiting
Key clinical trials
- Zorifertinib With Osimertinib for NSCLC With Meningeal Progression (PHASE1)
- First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases (PHASE2, PHASE3)
- Phase II Umbrella Study Directed by Next Generation Sequencing (PHASE2)
- Evaluate Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AZD3759 (PHASE1, PHASE2)
- Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AZD3759 CI brief — competitive landscape report
- AZD3759 updates RSS · CI watch RSS
- Guangdong Association of Clinical Trials portfolio CI